Search Results - "Pope, Ann M."

Development and validation of a follow-up methodology for a randomised controlled trial, utilising routine clinical data as an alternative to traditional designs: a pilot study to assess the feasibility of use for the BladderPath trial by Mintz, Harriet P, Dosanjh, Amandeep, Parsons, Helen M, Hughes, Ana, Jakeman, Alicia, Pope, Ann M, Bryan, Richard T, James, Nicholas D, Patel, Prashant

“…Bladder cancer outcomes have not changed significantly in 30 years; the BladderPath trial (Image Directed Redesign of Bladder Cancer Treatment Pathway,…”
Get full text

Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study by Bryan, Richard T., Liu, Wenyu, Pirrie, Sarah J., Amir, Rashid, Gallagher, Jean, Hughes, Ana I., Jefferson, Kieran P., Knight, Allen, Nanton, Veronica, Mintz, Harriet P., Pope, Ann M., Catto, James W.F., Patel, Prashant, James, Nicholas D.

“…Transurethral resection of bladder tumour (TURBT) is central to the diagnosis of muscle-invasive bladder cancer (MIBC). With the oncological safety of TURBT…”
Get full text

Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial by Tan, Wei Shen, Panchal, Anesh, Buckley, Laura, Devall, Adam J., Loubière, Laurence S., Pope, Ann M., Feneley, Mark R., Cresswell, Jo, Issa, Rami, Mostafid, Hugh, Madaan, Sanjeev, Bhatt, Rupesh, McGrath, John, Sangar, Vijay, Griffiths, T.R. Leyshon, Page, Toby, Hodgson, Dominic, Datta, Shibendra N., Billingham, Lucinda J., Kelly, John D.

“…There is no effective intravesical second-line therapy for non–muscle-invasive bladder cancer (NMIBC) when bacillus Calmette-Guérin (BCG) fails. To compare…”
Get full text

Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial by James, Nicholas D, Pirrie, Sarah J, Pope, Ann M, Barton, Darren, Andronis, Lazaros, Goranitis, Ilias, Collins, Stuart, Daunton, Adam, McLaren, Duncan, O'Sullivan, Joe, Parker, Christopher, Porfiri, Emilio, Staffurth, John, Stanley, Andrew, Wylie, James, Beesley, Sharon, Birtle, Alison, Brown, Janet, Chakraborti, Prabir, Hussain, Syed, Russell, Martin, Billingham, Lucinda J

“…Bony metastatic castrate-refractory prostate cancer (CRPC) has a poor prognosis and high morbidity. Zoledronic acid (ZA) is commonly combined with docetaxel in…”
Get more information